CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

NCT01033240 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Liver Cancer
Hepatic Cancer
Liver Neoplasms

Interventions

DRUG: CS-1008 2 mg/kg
DRUG: Sorafenib
DRUG: CS-1008 6/2 mg/kg
DRUG: CS-1008 6/6 mg/kg
DRUG: CS-1008 4 mg/kg
DRUG: CS-1008 6 mg/kg

Sponsor

Daiichi Sankyo